Analysis of 227 completed clinical trials reveals a fundamental shift in GLP-1 obesity research priorities. Liraglutide dominated with 86 studies, followed by semaglutide and tirzepatide with 18 each. Most trials enrolled under 200 participants and focused on Phase 3-4 investigations. Trial completion surged after 2018, coinciding with newer agent approvals. This trend analysis illuminates a critical evolution in obesity pharmacotherapy research. Early GLP-1 studies concentrated narrowly on weight reduction and glucose control—understandable given their diabetic origins. The documented pivot toward hepatic, cardiometabolic, and inflammatory endpoints reflects growing recognition that obesity is a complex metabolic disorder requiring multisystem intervention. This shift suggests researchers are finally addressing obesity's full pathophysiology rather than treating it as merely excess weight. The prevalence of smaller studies indicates the field remains in exploratory phases for many applications, though the Phase 3-4 focus suggests clinical maturity for core indications. The registry approach provides valuable meta-perspective but cannot assess trial quality or publication bias. This research landscape mapping suggests GLP-1 agents may emerge as broad metabolic modulators rather than simple weight-loss drugs.